283 related articles for article (PubMed ID: 20226822)
61. Enhanced chemotherapy efficacy by sequential delivery of siRNA and anticancer drugs using PEI-grafted graphene oxide.
Zhang L; Lu Z; Zhao Q; Huang J; Shen H; Zhang Z
Small; 2011 Feb; 7(4):460-4. PubMed ID: 21360803
[No Abstract] [Full Text] [Related]
62. Melittin liposomes surface modified with poloxamer 188: in vitro characterization and in vivo evaluation.
Tian JL; Ke X; Chen Z; Wang CJ; Zhang Y; Zhong TC
Pharmazie; 2011 May; 66(5):362-7. PubMed ID: 21699070
[TBL] [Abstract][Full Text] [Related]
63. Cationic phospholiposomes: efficient delivery vehicles of anticancer derivatives of ATP to multiple myeloma cells.
Wang L; MacDonald RC
J Liposome Res; 2011 Dec; 21(4):306-14. PubMed ID: 21457078
[TBL] [Abstract][Full Text] [Related]
64. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
[TBL] [Abstract][Full Text] [Related]
65. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: characterization and interaction with human lung fibroblasts.
Marianecci C; Paolino D; Celia C; Fresta M; Carafa M; Alhaique F
J Control Release; 2010 Oct; 147(1):127-35. PubMed ID: 20603167
[TBL] [Abstract][Full Text] [Related]
66. Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system.
Wu SY; Chang HI; Burgess M; McMillan NA
J Control Release; 2011 Nov; 155(3):418-26. PubMed ID: 21315117
[TBL] [Abstract][Full Text] [Related]
67. Carbon nanotubes-liposomes conjugate as a platform for drug delivery into cells.
Karchemski F; Zucker D; Barenholz Y; Regev O
J Control Release; 2012 Jun; 160(2):339-45. PubMed ID: 22245689
[TBL] [Abstract][Full Text] [Related]
68. A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro.
Urbán P; Estelrich J; Cortés A; Fernàndez-Busquets X
J Control Release; 2011 Apr; 151(2):202-11. PubMed ID: 21223986
[TBL] [Abstract][Full Text] [Related]
69. Non-ionic dendritic glycerol-based amphiphiles: novel excipients for the solubilization of poorly water-soluble anticancer drug Sagopilone.
Richter A; Wiedekind A; Krause M; Kissel T; Haag R; Olbrich C
Eur J Pharm Sci; 2010 Apr; 40(1):48-55. PubMed ID: 20188825
[TBL] [Abstract][Full Text] [Related]
70. Uptake and intracellular release kinetics of liposome formulations in glioma cells.
Bellavance MA; Poirier MB; Fortin D
Int J Pharm; 2010 Aug; 395(1-2):251-9. PubMed ID: 20573571
[TBL] [Abstract][Full Text] [Related]
71. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment.
Gomes-da-Silva LC; Santos AO; Bimbo LM; Moura V; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Int J Pharm; 2012 Sep; 434(1-2):9-19. PubMed ID: 22617794
[TBL] [Abstract][Full Text] [Related]
72. Targeted transfection increases siRNA uptake and gene silencing of primary endothelial cells in vitro--a quantitative study.
Asgeirsdóttir SA; Talman EG; de Graaf IA; Kamps JA; Satchell SC; Mathieson PW; Ruiters MH; Molema G
J Control Release; 2010 Jan; 141(2):241-51. PubMed ID: 19766679
[TBL] [Abstract][Full Text] [Related]
73. Polyvalent catanionic vesicles: exploring the drug delivery mechanisms.
Boudier A; Castagnos P; Soussan E; Beaune G; Belkhelfa H; Ménager C; Cabuil V; Haddioui L; Roques C; Rico-Lattes I; Blanzat M
Int J Pharm; 2011 Jan; 403(1-2):230-6. PubMed ID: 20974236
[TBL] [Abstract][Full Text] [Related]
74. Building and characterizing antibody-targeted lipidic nanotherapeutics.
Kirpotin DB; Noble CO; Hayes ME; Huang Z; Kornaga T; Zhou Y; Nielsen UB; Marks JD; Drummond DC
Methods Enzymol; 2012; 502():139-66. PubMed ID: 22208985
[TBL] [Abstract][Full Text] [Related]
75. Interactions of antitumour Sialyl Lewis X liposomes with vascular endothelial cells.
Alekseeva A; Kapkaeva M; Shcheglovitova O; Boldyrev I; Pazynina G; Bovin N; Vodovozova E
Biochim Biophys Acta; 2015 May; 1848(5):1099-110. PubMed ID: 25646577
[TBL] [Abstract][Full Text] [Related]
76. Analysis of lipid nanoparticles by Cryo-EM for characterizing siRNA delivery vehicles.
Crawford R; Dogdas B; Keough E; Haas RM; Wepukhulu W; Krotzer S; Burke PA; Sepp-Lorenzino L; Bagchi A; Howell BJ
Int J Pharm; 2011 Jan; 403(1-2):237-44. PubMed ID: 20974237
[TBL] [Abstract][Full Text] [Related]
77. Multivesicular liposome (MVL) sustained delivery of a novel synthetic cationic GnRH antagonist for prostate cancer treatment.
Wang T; Gao L; Quan D
J Pharm Pharmacol; 2011 Jul; 63(7):904-10. PubMed ID: 21635255
[TBL] [Abstract][Full Text] [Related]
78. Antiviral effect of HPMPC (Cidofovir®), entrapped in cationic liposomes: in vitro study on MDBK cell and BHV-1 virus.
Korvasová Z; Drašar L; Mašek J; Turánek Knotigová P; Kulich P; Matiašovic J; Kovařčík K; Bartheldyová E; Koudelka Š; Škrabalová M; Miller AD; Holý A; Ledvina M; Turánek J
J Control Release; 2012 Jun; 160(2):330-8. PubMed ID: 22326403
[TBL] [Abstract][Full Text] [Related]
79. Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging.
Bae KH; Lee JY; Lee SH; Park TG; Nam YS
Adv Healthc Mater; 2013 Apr; 2(4):576-84. PubMed ID: 23184673
[TBL] [Abstract][Full Text] [Related]
80. Efficient intracellular delivery of siRNA with a safe multitargeted lipid-based nanoplatform.
Gomes-da-Silva LC; Fernández Y; Abasolo I; Schwartz S; Ramalho JS; Pedroso de Lima MC; Simões S; Moreira JN
Nanomedicine (Lond); 2013 Sep; 8(9):1397-413. PubMed ID: 23394132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
